Uses of pyrimido-pyridazinones to treat cancer
Disclosed are methods of treating cancer, which include administering a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or ester thereof, to a subject in need thereof. Also disclosed are methods of inhibiting growth and proliferation of cancer cells in vitro or in vivo, which include contacting the cells with an amount of the compound of formula (I) effective to inhibit the growth or proliferation of the cancer cells. Further disclosed are methods of inhibiting tumor growth, which include contacting the tumor with an amount of the compound of formula (I) effective to inhibit the growth of the tumor.
1. A method of treating a cancer subject, comprising administering to a cancer subject in need thereof, a therapeutically effective amount of a compound 2-(1-(4-((4-(4-hydroxypiperidin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile, or a pharmaceutically acceptable salt or ester thereof, wherein:
the cancer subject has a recurrent or refractory cancer;
the cancer is a hematopoietic cancer; and
the cancer is refractory to Ibrutinib.
2. The method of claim 1 , wherein the compound is a salt of an acid and the acid is selected from the group consisting of acetic, propionic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, phthalic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, napthalenesulfonic, benzenesulfonic, toluenesulfonic, trifluoroacetic, and camphorsulfonic.
3. The method of claim 1 , wherein the hematopoietic cancer is lymphoma.
4. The method of claim 3 , wherein the lymphoma is diffuse large B-cell lymphoma.
5. The method of claim 3 , wherein the lymphoma is mantle cell lymphoma.
6. The method of claim 3 , wherein the lymphoma is follicular lymphoma.
7. The method of claim 1 , wherein the hematopoietic cancer is leukemia.
8. The method of claim 7 , wherein the leukemia is acute myeloid leukemia (AML).
9. The method of claim 8 , wherein the AML is human erythroleukemia.
10. The method of claim 1 , wherein the hematopoietic cancer is multiple myeloma.
11. The method of claim 1 , wherein the cancer subject is a mammal.
12. The method of claim 11 , wherein the mammal is human.
13. The method of claim 1 , wherein the compound is administered orally.
14. The method of claim 1 , wherein the compound is administered parenterally.
15. The method of claim 14 , wherein the compound is administered via injection.
16. The method of claim 1 , wherein the compound is formulated in a dosage form further comprising a pharmaceutically acceptable carrier.
17. The method of claim 1 , wherein the cancer subject has undergone a prior anti-cancer treatment regimen.